卖什么
干细胞/前体细胞产品。
商业模式拆解
买家：谁掌握预算？
未核实Not applicable yet: pre-commercial; payer would be patients/health systems if approved.
触发点：什么让他们现在购买？
Severe irreversible organ damage (COPD, IPF, CKD) that conventional drugs cannot address.
工作流：什么输入变成什么输出？
Tissue-specific epithelial progenitor cell therapy (REGEND001 for lung, REGEND003 for kidney) to repair organ structure and function; patients can join clinical trials.
经济账：省了什么，怎么收费？
未核实Clinical-stage biotech; revenue would come from commercializing cell therapy products; none shown.
渠道：怎么接触到客户？
Clinical-trial recruitment via a patients center; no commercial channel yet.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-02-11 | C 轮 | 3.5亿元 | 禹泽资本, 合肥高投, 洪泰基金 and others | xhby.net |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.